Distinct temporal and spatial activities of RU486 on progesterone receptor function in reproductive organs of ovariectomized mice
- PMID: 17303655
- DOI: 10.1210/en.2006-1561
Distinct temporal and spatial activities of RU486 on progesterone receptor function in reproductive organs of ovariectomized mice
Abstract
RU486 is an incomplete progesterone receptor (PR) antagonist due to its partial agonist activity. To investigate the tissue-specific effects of RU486 on PR function in an ovariectomized mouse model, we used the progesterone receptor activity indicator mouse and evaluated the key determinants of progesterone-dependent gene activity: PR, coregulators, and kinases. As might be expected, acute RU486 treatment (6 h after injection) reduced PR transcriptional activity in the uterus, compared with vehicle or progesterone (P4) treatments. Chronic RU486 treatment (3 d) had a distinctly different effect on PR-mediated transcription, elevating PR activity in both the uterus and mammary gland, whereas chronic P4 treatment reduced PR activity in both tissues. This elevated uterine PR activity was associated with increased modified forms of PR and total protein levels of steroid receptor coactivator (SRC)-1 without affecting SRC-2 or SRC-3 protein levels. In addition to increased levels of coactivators, chronic RU486 treatment activated the ERK-1/2 and c-Jun N-terminal kinase signaling pathways in the uterus in a manner comparable with P4 treatment. In contrast to our observations in the uterus, chronic RU486 treatment increased modified forms of PR and the SRC-3 protein levels (but not SRC-1 and SRC-2 levels) in luminal epithelial cells of the mammary gland. Chronic RU486 also activated the c-Jun N-terminal kinase, but not ERK-1/2, signaling pathways in mammary luminal epithelial cells. This report suggests that in comparison with chronic natural hormone (P4), a mixed antagonist/agonist (RU486) induces a distinct temporal and spatial pattern of cellular genetic regulators that accompany ligand-specific gene expression.
Similar articles
-
Steroid receptor coactivator (SRC)-1 and SRC-3 differentially modulate tissue-specific activation functions of the progesterone receptor.Mol Endocrinol. 2006 Jan;20(1):45-55. doi: 10.1210/me.2005-0310. Epub 2005 Sep 1. Mol Endocrinol. 2006. PMID: 16141356
-
Steroid receptor coactivator 2 is critical for progesterone-dependent uterine function and mammary morphogenesis in the mouse.Mol Cell Biol. 2006 Sep;26(17):6571-83. doi: 10.1128/MCB.00654-06. Mol Cell Biol. 2006. PMID: 16914740 Free PMC article.
-
Hormone-dependent interaction between the amino- and carboxyl-terminal domains of progesterone receptor in vitro and in vivo.Mol Endocrinol. 1999 Jun;13(6):910-24. doi: 10.1210/mend.13.6.0300. Mol Endocrinol. 1999. PMID: 10379890
-
Steroid receptor coactivator 2 is essential for progesterone-dependent uterine function and mammary morphogenesis: insights from the mouse--implications for the human.J Steroid Biochem Mol Biol. 2006 Dec;102(1-5):22-31. doi: 10.1016/j.jsbmb.2006.09.007. Epub 2006 Oct 12. J Steroid Biochem Mol Biol. 2006. PMID: 17045797 Review.
-
Dynamic regulation of progesterone receptor activity in female reproductive tissues.Ernst Schering Found Symp Proc. 2007;(1):25-43. doi: 10.1007/2789_2007_056. Ernst Schering Found Symp Proc. 2007. PMID: 18543433 Review.
Cited by
-
Research resource: Transcriptional profiling in a cellular model of breast cancer reveals functional and mechanistic differences between clinically relevant SERM and between SERM/estrogen complexes.Mol Endocrinol. 2012 Jul;26(7):1235-48. doi: 10.1210/me.2012-1031. Epub 2012 May 8. Mol Endocrinol. 2012. PMID: 22570330 Free PMC article.
-
Up-regulation of circadian clock gene Period 2 in the prostate mesenchymal cells during flutamide-induced apoptosis.Mol Cell Biochem. 2010 Feb;335(1-2):37-45. doi: 10.1007/s11010-009-0238-7. Epub 2009 Aug 28. Mol Cell Biochem. 2010. PMID: 19714448
-
Tracking progesterone receptor-mediated actions in breast cancer.Pharmacol Ther. 2014 Apr;142(1):114-25. doi: 10.1016/j.pharmthera.2013.11.010. Epub 2013 Nov 26. Pharmacol Ther. 2014. PMID: 24291072 Free PMC article. Review.
-
Discovery of Vilaprisan (BAY 1002670): A Highly Potent and Selective Progesterone Receptor Modulator Optimized for Gynecologic Therapies.ChemMedChem. 2018 Nov 6;13(21):2271-2280. doi: 10.1002/cmdc.201800487. ChemMedChem. 2018. PMID: 30407750 Free PMC article.
-
Ligand-dependent degradation of SRC-1 is pivotal for progesterone receptor transcriptional activity.Mol Endocrinol. 2011 Mar;25(3):394-408. doi: 10.1210/me.2010-0458. Epub 2011 Jan 27. Mol Endocrinol. 2011. PMID: 21273440 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous